CEDRA Corporation Names CEO

CEDRA Corporation Names CEO
AUSTIN, Texas--(BUSINESS WIRE)--CEDRA Corporation, a division of Worldwide Clinical Trials (WCT) and a provider of Phase I clinical research and bioanalytical services, announced today that Anthony G. Busa, Jr., has been named Chief Executive Officer.

"He will be a great asset to our team in terms of growth and management."
.Busa has over 34 years of experience in management positions including senior level management, regional and national sales and product development within the pharmaceutical and medical device industries. His new position at CEDRA will utilize his core values and strategic vision developed throughout decades of experience.

"Anthony is an experienced, high caliber professional. He has a thorough understanding of how this business and industry functions," stated Worldwide Clinical Trials Chief Operating Officer, Tom Wardle. "He will be a great asset to our team in terms of growth and management."

Busa received his Bachelor of Science degree in biology from Iona College, located in New Rochelle, NY. He is a member of Drug Information Association (DIA), American Management Association (AMA) and Healthcare Manufacturer's Marketing Council, Inc. (HMMC).

Previously, Busa held senior management related positions at McClintic Busa Group, LLP, dgd Research, Inc., Esoterix, Inc., Medsites, Inc., and Covance, Inc.

About CEDRA
CEDRA Corporation, a division of Worldwide Clinical Trials, offers a full range of Phase I-IIb clinical research and bioanalytical services, as well as specialized studies to the pharmaceutical/biotech and medical device industries. CEDRA's combination of a state-of-the-art bioanalytical laboratory with clinical research sites allows them to play an important role in drug development programs. To learn more about CEDRA, visit www.cedracorp.com.


Contacts
SCORR Marketing
Kelly Sladek, 308-237-5567
[email protected]

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.